Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment
Open Access
- 25 September 2016
- journal article
- review article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 22 (3) , 327-335
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a "hot potato" for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat NAFLD. However, there are several challenging issues regarding the diagnosis of NAFLD. Currently, liver biopsy is the gold standard method for the diagnosis of NAFLD and steatohepatitis. Ideally, globally recognized standards for histological diagnosis and methods to optimize observer agreement on biopsy interpretation should be developed. Liver biopsy is the best method rather than a perfect one. Recently, multi-parametric magnetic resonance imagery can estimate the amount of intrahepatic fat successfully and is widely used in clinical trials. But no diagnostic method can discriminate between steatohepatitis and simple steatosis. The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options. Vitamin E and obeticholic acid have shown protective effects in randomized controlled trials, but this drug has not been approved for use in Korea. This study will provide a description of diagnostic methods and treatments that are currently recommended for NAFLD.Keywords
This publication has 57 references indexed in Scilit:
- ISMRM workshop on fat–water separation: Insights, applications and progress in MRIMagnetic Resonance in Medicine, 2012
- An apoptosis panel for nonalcoholic steatohepatitis diagnosisJournal of Hepatology, 2011
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §ΔHepatology, 2010
- The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysisEuropean Radiology, 2010
- Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 DiabetesDiabetes Care, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)BMC Gastroenterology, 2008
- Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markersHepatology, 2008
- The NAFLD fibrosis scoreHepatology, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005